Abingworth
Life sciences investor funding biotech companies developing new therapeutics
- Venture capital
- London
- Type
- Venture capital
- Based in
- London
- Stages
- Pre-seed, Seed, Series A, Series B+, Growth
- Sector focus
- Sector-agnostic
- Cheque size
- Above €3M
- Fund size
- Undisclosed
- Founded
- 1987
- Website
- abingworth.com
A life sciences investment firm founded in 1987 and headquartered in London, with further offices in New York and San Francisco. It backs entrepreneurs turning scientific discoveries into new medicines, concentrating on biotech and biopharma companies.
Early-stage venture investment is central to its approach, and it also uses venture investments in public equities (VIPEs) and clinical co-development deals, where it funds late-stage trials of drug candidates. The firm says it has invested in more than 100 biotech companies since it was established.
← All investors · Is this your organisation? Request an update
More investors in the directory
Scottish EDGE
Scotland's largest business funding competition, GBP 10k–150k grants and loans; backed Prozymi Biolabs and Unbaggaged
Railpen
UK railways pension manager (c. GBP 36bn) investing in private markets; backed CMR Surgical and Gousto
NVIDIA
US chipmaker investing in AI startups via NVentures; backed Nscale and PhysicsX
Norrsken Accelerator
Stockholm impact accelerator, now Norrsken Evolve, writing EUR 250–500k pre-seed cheques; backed Furbnow and Kavaken
NEA
US multi-stage technology and healthcare VC founded 1977; backed CuspAI and ElevenLabs
NATO Innovation Fund
EUR 1bn multi-sovereign deep-tech VC backed by NATO allies; backed Aquark Technologies and Uplift360
Subscribe to Newsletter
UK startup news, founder stories and funding insight, straight to your inbox every week. Free.